| Epidemiology

Persistence to Onabotulinumtoxina versus Calcitonin Gene-related Peptide Monoclonal Antibodies (CGRP Mabs) Among Migraine Patients in a US Electronic Health Record Database

book_2 Source: AHSAM 2020 - Poster session Published on September 3, 2020
calendar_today Published on Medfyle: August 2020
headphones 2 min

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

  • This study evaluated early real-world persistence among 1976 adults with migraine treated with onabotulinumtoxinA or CGRP mAbs
  • In real-world practice, patients showed higher levels of persistence on onabotulinumtoxinA compared to CGRP mAbs for migraine
  • This was also true among patients with chronic migraine or episodic migraine
Presenting Author
Read more arrow_downward Hide arrow_upward

Amy Tung, PharmD, MS
Associate Director
Allergan plc
Irvine, California

Amy Tung, PharmD, MS, is an Associate Director in the Health Economics Outcomes Research group at Abbvie Inc (formerly Allergan Plc). She received her Doctorate of Pharmacy and Master in Science in Health Economics Outcomes Research from the University of Washington in Seattle, Washington. Amy currently resides in Huntington Beach, California.

Author disclosures
Read more arrow_downward Hide arrow_upward

Amy Tung, PharmD, MS: Allergan (Employment) (Salary)